These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8622053)

  • 21. Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer.
    Prat A; Parera M; Del Campo JM
    J Clin Oncol; 2008 Apr; 26(10):1771-2; author reply 1772. PubMed ID: 18375912
    [No Abstract]   [Full Text] [Related]  

  • 22. Second-line chemotherapy of epithelial ovarian cancer.
    Markmon M
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):31-6. PubMed ID: 12597347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial.
    Markman M; Petersen J; Belland A; Burg K
    Oncology; 2010; 78(1):1-2. PubMed ID: 20215782
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: "clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation".
    Menczer J
    Gynecol Oncol; 2005 Mar; 96(3):906-7; author reply 907. PubMed ID: 15721450
    [No Abstract]   [Full Text] [Related]  

  • 25. [Contribution of dynamic interpretation of CA 125 measurements to the understanding of an atypical clinical case].
    Riedinger JM; Mousseau M; Gauchez AS
    Ann Biol Clin (Paris); 2008; 66(3):333-40. PubMed ID: 18558573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients.
    Paulsen T; Marth C; Kaern J; Nustad K; Kristensen GB; Tropé C
    Gynecol Oncol; 2000 Mar; 76(3):326-30. PubMed ID: 10684705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Second-line chemotherapy and new drugs for ovarian carcinoma].
    Priolo D; Antonelli G; Calì S; Colina P; Giuffrida D; Malaponte E; Mattina M; Parisi A; Sambataro D; Vitale F; Ferraù F
    Clin Ter; 2001; 152(1):39-50. PubMed ID: 11382169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma.
    Gadducci A; Menichetti A; Guiggi I; Notarnicola M; Cosio S
    Anticancer Res; 2015 Feb; 35(2):1099-104. PubMed ID: 25667499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer.
    Markman M
    Gynecol Oncol; 1993 Dec; 51(3):297-8. PubMed ID: 8112634
    [No Abstract]   [Full Text] [Related]  

  • 30. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [CA-125 as response parameter in ovarian carcinoma].
    Zirpel I; Illiger HJ
    Strahlenther Onkol; 2000 Apr; 176(4):200. PubMed ID: 10841742
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer.
    Nielsen HA; Nielsen D; Engelholm SA
    Gynecol Oncol; 2000 Jun; 77(3):383-8. PubMed ID: 10831346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian cancer, CA-125 addiction, and informed confusion: much ado about less.
    Tummala MK; McGuire WP
    J Clin Oncol; 2007 Aug; 25(24):3570-1. PubMed ID: 17704402
    [No Abstract]   [Full Text] [Related]  

  • 35. A doctor talks about. Screening for ovarian cancer.
    Robb-Nicholson C
    Harv Womens Health Watch; 2004 Sep; 12(1):5. PubMed ID: 15381472
    [No Abstract]   [Full Text] [Related]  

  • 36. CA 125 half-life breakpoint between a "good" and "poor" prognosis in patients with ovarian cancer.
    Mano A; Godinho I; Falcão AC
    Int J Gynaecol Obstet; 2005 Mar; 88(3):333-5. PubMed ID: 15733897
    [No Abstract]   [Full Text] [Related]  

  • 37. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
    Herzog TJ; Vermorken JB; Pujade-Lauraine E; Provencher DM; Jagiello-Gruszfeld A; Kong B; Boman K; Park YC; Parekh T; Lebedinsky C; Gómez J; Monk BJ
    Gynecol Oncol; 2011 Aug; 122(2):350-5. PubMed ID: 21546066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer.
    Søgaard CH; Lindegaard JC; Havsteen H; Nielsen OS; Mogensen O
    Gynecol Oncol; 2005 May; 97(2):410-2. PubMed ID: 15863138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rising CA-125 levels in a patient with ovarian cancer are not always indicative of disease recurrence].
    Yerushalmi R; Rakowsky E; Sulkes A
    Harefuah; 2002 Apr; 141(4):347-8, 410. PubMed ID: 12017887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.